New indications for growth hormone

Archives of Disease in Childhood: Education and Practice Edition

Volumn 90, Issue 1, 2005, Pages

  Bridges, Nicola ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

DISEASE EXACERBATION; DRUG FATALITY; EDEMA; EPIPHYSIOLYSIS; FEMUR EPIPHYSIS; GROWTH HORMONE DEFICIENCY; GYNECOMASTIA; HORMONAL THERAPY; HUMAN; IDIOPATHIC DISEASE; INSULIN RESISTANCE; INTRACRANIAL HYPERTENSION; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRADER WILLI SYNDROME; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCOLIOSIS; SHORT STATURE; SHORT SURVEY; SMALL FOR DATE INFANT; SUDDEN DEATH; TREATMENT OUTCOME; TURNER SYNDROME;

EID: 20144363953     PISSN: 17430585     EISSN: None     Source Type: Journal    
DOI: 10.1136/adc.2004.061382     Document Type: Short Survey

References (42)

1. National Institute for Clinical Excellence. Full guidance on the use of human growth hormone in children with growth failure. National Institute for Clinical Excellence No 42, 2002.
2. Sybert VP, Mccauley, E. Medical progress - Turner's syndrome. N Engl J Med 2004;351:1227-38.
3. Lyon AJ, Preece MA, Grant DB. Growth curve for girls with Turner syndrome. Arch Dis Child 1985;60:932-5.
4. Hochberg Z, Zadik Z. Final height in young women with Turner syndrome after GH therapy: an open controlled study. Eur J Endocrinol 1999;141:218-24.
5. Canadian Growth Hormone Advisory Committee. GH treatment to final height in Turner syndrome: a randomised controlled trial [abstract]. Horm Res 1998;50(suppl):25.
6. Gault EJ, Paterson WF, Young D, et al. Improved final height in Turner's syndrome following growth promoting treatment at a single centre. Acta Paediatr 2003;92:1033-8.
7. Guyda HJ. Four decades of growth hormone therapy for short children: what have we achieved? J Clin Endocrinol Metab 1999;84:4307-16.
8. Bryant J, Cave C, Mihaylova B, et al. Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Health Technol Assess 2002;6:1-168.
9. Bakalov VK, Cooley MM, Quon MJ, et al. Impaired insulin secretion in the Turner metabolic syndrome. J Clin Endocrinol Metab 2004;89:3516-20.
10. Sas T, de Muinck Keizer-Schrama S, Aanstoot HJ, et al and the Dutch Advisory Group on Growth Hormone. Carbohydrate metabolism during growth hormone treatment and after discontinuation of growth hormone treatment in girls with Turner syndrome treated with once or twice daily growth hormone injections. Clin Endocrinol 2000;52:741-7.
11. Wollmann HA, Schultz U, Grauer ML, et al. Reference values for height and weight in Prader Willi syndrome based on 315 patients. Eur J Pediatr 1997;157:634-42.
12. Corrias A, Bellone J, Beccaria L, et al. GH/IGF1 axis in Prader Willi syndrome: evaluation of IGF1 levels and of the somatotroph resposiveness to various provocative stimuli. Genetic obesity study group of Italian Society of Paediatric Endocrinology and Diabetology. J Endocrinol Invest 2000;23:84-9.
13. Schmidt H, Schwarz HP, Enders A. Dietary intervention in the first 4 years prevents abnormal weight gain but negatively affects height development in Prader Willi syndrome [letter]. Acta Paediatr 2001;90:468-9.
14. Carrel AL, Myers SE, Whitman BY, et al. Benefits of long term GH therapy in Prader Willi syndrome: a 4 year study. J Clin Endocrinol Metab 2002;87:1581-5.
15. Lindgren AC, Ritzen EM. Five years of growth hormone treatment in children with Prader Willi syndrome. Acta Paediatr (suppl) 1999;433:109-11.
16. Lindgren AC, Hagenas, Muller J, et al. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Pediatr 1998;87:28-31.
17. Haqq AM, Stadler DD, Jackson RH, et al. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi Syndrome. J Clin Endocrinol Metab 2003;88:2206-12.
18. Myers SE, Carrel AL, Whitman BY, et al. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr 2000;137:42-9.
19. Whittington JE, Holland AJ, Webb T, et al. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK health region. J Med Genet 2001;38:792-8.
20. Butler JV, Whittington JE, Holland AJ, et al. Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study. Dev Med Child Neurol 2002;44:248-55.
21. Hoybye C, Hilding A, Jacobsson H, et al. Growth hormone treatment improves body composition in Prader Willi syndrome. Clin Endocrinol 2003;58:653-61.
22. Vliet GV, Deal CL, Crock PA, et al. Sudden death in growth hormone treated children with Prader Willi syndrome. J Pediatr 2004;144:129-31.
23. Eiholzer U, Nordmann Y, L'Allemand D. Fatal outcome of sleep apnoea during the inital phase of growth hormone treatment. A case report. Horm Res 2002;59(suppl 3):24-6.
24. Karlberg J, Albertsson-Wikland K. Growth in full-term small-for-gestational-age infants: from birth to adult height. Pediatr Res 1995;38:733-9.
25. Johnston LB, Savage MO. Should recombinant human growth hormone therapy be used in short small for gestational age children? Arch Dis Child 2004;89:740-4.
26. Van Pareren YV, Mulder P, Houdijk M, et al. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab 2003;88:3584-90.
27. Carel JC, Chatelain P, Rochiccioli P, et al. Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomised controlled study. J Clin Endocrinol Metab 2003;88:1587-93.
28. De Zegher F, Albertsson-Wickland K, Wollman HA, et al. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years. J Clin Endocrinol Metab 2000;85:2816-21.
29. Woods KA, Van Helvoirt M, Ong KKL, et al. The somatotropic axis in short children born small for gestational age: relation to insulin resistance. Pediatr Res 2002;51:76-80.
30. Levy-Marchal C, Jaquet D, Czernichow P. Long-term metabolic consequences of being born small for gestational age. Semin Neonatal 2004;9:67-74.
31. Barker DJ, Hales CN, Fall CH, et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993;36:62-7.
32. De Zegher F, Ong K, van Helvort M, et al. High dose growth hormone (GH) treatment in non GH deficient children born small for gestational age induces GH responses related to pre-treatment GH secretion and associated with a reversible decrease in GH sensitivity. J Clin Endocrinol Metab 2002;87:148-51.
33. Van Pareren YV, Mulder P, Houdijk M, et al. Effect of discontinuation of growth hormone treatment on risk factors for cardiovascular disease in adolescents born small for gestational age. J Clin Endocrinol Metab 2003;88:347-53.
34. Leschek EW, Rose SR, Yanovski JA, et al. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomised double blind placebo controlled trial. J Clin Endocrinol Metab 2004;89:3140-8.
35. Freemark M. Growth hormone treatment of "idiopathic short stature": not so fast. J Clin Endocrinol Metab 2004;89:3138-9.
36. Swerdlow AJ, Higgins CD, Adlard P, et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002;360:273-7.
37. Juul A, Bernasconi S, Carel JC, et al, Drugs and Therapeutics Committee of the European Society for Paediatric Endocrinology. Growth hormone treatment and risk of solid tumours. A statement from the Drugs and Therapeutics Committee of the European Society for Paediatric Endocrinology (ESPE). Horm Res 2003;60:103-4.
38. Sas TCJ, De Muinck Keizer-Schrama SMPF, Stijnen T, et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab 1999;84:4607-12.
39. Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000;355:610-13.
40. Lee PA, Kendig JW, Kerrigan JR. Persistant short stature, other potential outcomes and the effect of growth hormone treatment in children who are born small for gestational age. Pediatrics 2003;112:150-62.
41. Sandberg DE, Voss LD. The psychosocial consequences of short stature - a review of the evidence. Ballieres Best Pract Res Clin Endocrinol Metab 2002;16:449-63.
42. Ulph F, Betts P, Mulligan J, et al. Personality functioning: the influence of stature. Arch Dis Child 2004;89:17-21.